GPX3 and benign prostatic hyperplasia: We further used 20 μM GSK621 (AMPK agonist, the IC50 of GSK621 on cytotoxic of BPH-1 and WPMY-1 cells were 23.21 μM and 25.33 μM, respectively) (Additional file 10: Fig. S6F) pretreatment to determine whether AMPK was associated with GPX3-mediated autophagy.